Demographic and Clinical Factors Associated with Development of Brimonidine Tartrate 0.2%-Induced Ocular Allergy

Journal of Glaucoma

Volumn 13, Issue 2, 2004, Pages 163-167

  Manni, Gianluca ^a,b   Centofanti, Marco ^a,b   Sacchetti, Marta ^a   Oddone, Francesco ^a   Bonini, Stefano ^b,c   Parravano, Mariacristina ^a   Bucci, Massimo Gilberto ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Brimonidine; Drug toxicity; Glaucoma

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; STEROID;

ADULT; AGED; ARTICLE; CLOSED ANGLE GLAUCOMA; CONJUNCTIVITIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; RISK FACTOR; SCHIRMER TEST; TEAR FILM;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CONJUNCTIVITIS, ALLERGIC; DEMOGRAPHY; DERMATITIS, ALLERGIC CONTACT; DRUG HYPERSENSITIVITY; EYELID DISEASES; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; QUINOXALINES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 1642399896     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200404000-00014     Document Type: Article

References (22)

1. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41(Suppl 1): S19-S26.
2. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847-852.
3. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41(Suppl 1):S39-S47.
4. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol. 1995;113:77-83.
5. Thompson CD, Macdonald TL, Garst ME, et al. Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation. Exp Eye Res. 1997;64:767-773.
6. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999;127:20-26.
7. Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37:21-26.
8. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther. 2000;22:103-111.
9. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998;105:1960-1967.
10. Abelson MB, LeMaitre NC. How to diagnose hypersensitivity reactions. Review of Ophthalmology. 1999;6:104-106.
11. Jackson WB. Differentiating conjunctivitis of diverse origins. Surv Ophthalmol. 1993;38:91-104.
12. Shin DH, Glover BK, Cha SC, et al. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am J Ophthalmol. 1999; 127:511-515.
13. Abelson MB, Chapin, M, Batoosingh, A, et al. A retrospective examination of drug-induced allergy to Alphagan and a proposal for a new reporting system. Invest Ophthalmol Vis Sci. 1999;40:S515.
14. Bonini S, Lambiase A, Juhas T, et al. Allergic conjunctivitis. Dev Ophthalmol. 1999;30:54-61.
15. Dinowitz M, Rescigno R, Bielory L. Ocular allergic diseases: differential diagnosis, examination techniques, and testing. Clin Allergy Immunol. 2000;15:127-150.
16. Burnstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980;19:308-313.
17. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119-126.
18. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
19. Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45(Suppl 2):S211-S220.
20. Sherwood MB, Grierson I, Millar L, et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989;96:327-335.
21. de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232: 221-224.
22. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419-425.